Thursday, March 26, 2020

IBI Research On BioSig Technologies: The Answer For Coronavirus

The Coronavirus pandemic has infected over 400K people while killing more than 18K lives.
Aside from the medical devastation, the Coronavirus is exerting heavy pressure on the global economy.
Amid the worldwide quarantine, many companies shut down their operation.
Coronavirus will plateau by the end of April. And it should be gone by the end of August. However, it can come back again in milder form like the flu.
Through its subsidiaries, BioSig is advancing a highly promising antiviral against Coronavirus. As such, this investment can help you make a lot of money in the near term.
Bull markets are born on pessimism, grown on skepticism, mature on optimism and die on euphoria. - Sir John Templeton
Author's Note: This article was published inside IBI on March 26, 2020 at 2:16 am ET.

You're now several weeks into the 2019 Corona bear market. And, most of your stocks substantially declined. You've lived through the day with the Dow dropping nearly 13%. That's the worst drop since 1987. As fast as this bear market knocks you off your feet, it also rebounds most vigorously. In other words, your stocks have been rallying robustly for two consecutive days. Specifically, the DOW is recovering to trade over 21,200 points today.
As you can see, the best opportunity to purchase stocks is during a bear market. If you bought BioSig Technologies (NASDAQ:BSGM) when I made my recommendation, you'd already enjoyed over 25% profits. Don't worry. The best is yet to come! BioSig is undergoing ground-breaking development. That is to say, it recently acquired a drug that can cure Coronavirus. In this article, I'll present a fundamental analysis of BioSig and provide my updated expectations on this intriguing grower.
Figure 1: BioSig chart (Source: StockCharts)

About The Company

As usual, I'll present a brief corporate overview for new investors. If you are familiar with the company, you should skip to the subsequent section. Headquartered in Westport, Connecticut, BioSig is engaged in the innovation and commercialization of premier technology to serve the unmet needs in the electrophysiology market. Through its subsidiary, the company also innovates promising medicine to treat Coronavirus.
Figure 2: Business overview (Source: BioSig)

NeuroClear Subsidiary

In bioscience investing, it's essential that you look for any hidden asset in the company. Asides from PURE EP, I realized that BioSig has a majority-owned subsidiary dubbed NeuroClear. In my view, NeuroClear is a hidden gem. When you take into account NeuroClear, BioSig should be worth far more than its current valuation. That being said, let's check into NeuroClear's recent development.
On March 25, BioSig announced that NeuroClear acquired the rights to Vicromax. It's a molecule that can potentially cure Coronavirus (i.e. COVID-19).
As you know, Coronavirus is a serious world health threat. The Situation Report from the World Health Organization (i.e., W.H.O.) is jaw-dropping. Altogether, the Coronavirus pandemic has infected 414,179 people while killing 18,440 lives. Adding further injury to the insult, the statistics are rising.
Figure 3: Situation report (Source: WHO)
In addition to the death tolls, Coronavirus puts a strain on the global economy. For instance, many countries have implemented quarantine. As a result, businesses are being closed down across the globe.

IBI Research On BioSig Technologies: Revolutionizing The Electrophysiology Market

The Corona bear market is offering stellar buying opportunities.
Fundamentally strong stocks are trading at a deep bargain to their intrinsic value.
BioSig Technologies is another company that you should pick up.
Powered by its disruptive PURE EP technology, BioSig is poised to change the electrophysiology market.
The company is undergoing robust fundamental improvements that will unlock tremendous value.
For all long-term investors, there is only one objective - maximum total real return after taxes. - Sir John Templeton
Author's Note: This article was published inside IBI on March 23, 2020 at 2:44 am ET.

Corona Bear Market Opportunity

By now, I bet that you're sick of hearing about the 2020 Corona bear market. As the pandemic ramps up its death toll, market fear is at an all-time high. Nearly all investors are terrified when their stocks fall into a seemingly bottomless pit. Due to that pervasive market fear, many investors sold out of their holdings. As such, their temporary paper losses turned into real losses. Adding further injury to the insults, some will never enter the stock market again due to this pain.
Remember the saying, "no pain, no gain"? It's true! Contrary to conventional wisdom, your best time to buy stocks is during a bear market. And the time to sell is before the fall. As you can see, you can now pick up the same company at a dime for a dollar. Doing so would position you to earn multiple fold returns at the next bull market. In this research, I'll feature a fundamental analysis of another promising bio-stock, i.e., BioSig Technologies (NASDAQ:OTC:BSGM). If you're opportunistic and bold, you don't want to miss out on BioSig.
Figure 1: BioSig chart (Source: StockCharts)

About The Company

As usual, I'll present a brief corporate overview for new investors. If you are familiar with the company, you should skip to the subsequent section. Operating out of Westport, Connecticut, BioSig is focused on the innovation and commercialization of stellar technologies to serve the unmet needs in the electrophysiology market. That is to say, the fruit of its ingenuity improves the outcomes of heart surgeries relating to arrhythmias.
Figure 2: Business overview (Source: BioSig)

Cardiac Arrhythmia 

Since BioSig tackles cardiac arrhythmia, you should learn the disease fundamentals. As a group of disorders, cardiac arrhythmia epitomizes abnormal heartbeats. This disruptive pattern is further classified as an irregular heart rhythm that is either too fast or slow. Underlying the culprit for the disease is an abnormal electrical conduction pathway in the heart.

Wednesday, January 29, 2020

IBI Research On Avalon: Mega Partnerships For Rapid Pipeline Advancement

Despite its young age, Avalon Globocare is aggressively progressing on multiple fronts.
In mid-2019, the company secured a colossal partnership with GE Healthcare.
Avalon recently revealed another partnership. That is with China Nanjing Cell Valley.
This collaboration enabled Avalon to expedite its clinical advancement for the next-generation CAR-T.
Amid strong fundamental development, the stock is trading at a deep bargain to its true worth.
Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble. - Warren Buffett 
As you can see, all giant biotech companies have to start from somewhere. That is to say, Merck (MRK) didn't become a mega bio-stock overnight. It takes time, tremendous intelligence, and capital to nurture a young biotech to become a giant pharma of the future. Hence, if you invest in a powerful young bio company, you just found your ticket to a luxurious retirement. Now doesn't mean that you'll suddenly become rich overnight. You need to conquer the volatility associated with your bio-stock. And you can do that by being patient in holding your shares for the long haul. Better yet, you should build more stakes at opportunistic occasions, i.e. at the dips.
That being said, I'm attracted to Avalon Globocare (OTC:AVCO) because of its stellar management, premier chimeric antigen receptor (CAR-T), regenerative medicines, and exosomes empowered diagnostics. If you've been following my work on CAR-Ts, you'd know that I like Kite Pharma (KITE) and Juno Therapeutics (JUNO) that are acquired. Make no doubt, they have excellent CAR-Ts. Nevertheless, Avalon's CAR-Ts are far more advanced than any first-generation drugs. With signs of rapid advancement, it's spaghetti to sauce that Avalon will become a giant pharma one day. In this research, I'll feature a fundamental analysis on Avalon and provide my expectations of this Philip Fisher growth equity.
Figure 1: Avalon chart (Source: StockCharts)

About The Company

As usual, I'll present a brief corporate overview for new investors. If you are familiar with the firm, I suggest that you skip to the subsequent section. Based in Freehold, New Jersey, Avalon is engaged in the innovation and commercialization of novel medicines and disruptive diagnostics. Driven by tireless efforts, the company is poised to serve the global unmet needs in cancer and various conditions.
Of corporate strategy, Avalon employs a trident-like approach of Poseidon. In other words, the company captures opportunities in three lucrative niches. They include exosomes diagnostics, regenerative medicine, and cellular immunotherapy (i.e. CAR-T). As shown below, there are several potential blockbusters, including AVA-101, -201, and -203.
Figure 2: Diagnostic and therapeutic pipeline (Source: Avalon)
Regarding the diagnostic portfolio, Avalon reaps the ingenious science of "exosomal biomarkers" to launch an avalanche against oral cancer, nonalcoholic steatohepatitis ("NASH"), leukemia, colorectal cancer, and macular degeneration. Though there are different biomarkers, I strongly believe that exosomes are best. In my view, exosomes can pinpoint the diagnosis to confer physicians an edge against deadly conditions.

Mega Partnership To Signal Rapid Pipeline Advancement

Shifting gears, you should analyze important growth catalysts. Notably, I pay close attention to a bioscience innovator's ability to form partnerships. That's because it foretells pipeline advancement. After all, it's extremely difficult for a small company to go at it alone in development and commercialization. By collaborating, a young company can leverage its partner's expertise and infrastructure to expedite the drug development process.
So back on June 22, 2019, Avalon revealed a highly strategic partnership with GE Healthcare. It enabled Avalon to improve business logistics such as automation and standardization for good manufacturing practice (i.e GMP). It's a huge step in expanding Avalon's global cell production capabilities. Ultimately, it positioned the firm to become an undisputed leader in cell-based medicine. I wrote in the prior article,
The partnership will galvanize Avalon's capability to answer the strong demand for cell-based therapies worldwide. The company can now ramp up its supply of clinical-grade cellular products consisting of CAR-T, CAR-NK (natural killer cells), and stem cell-derived exosomes. Specifically, it ensures an adequate supply of biological specimens through scale-up manufacturing throughput and efficiency. Moreover, standardization and automation improve the specimen's uniformity.

China Nanjing Cell Valley Catalyst

Aside from GE Healthcare, Avalon disclosed another powerful partnership on December 20, 2019. That is to say, the company is collaborating with China (Nanjing) Cell Valley (i.e. Cell Valley). The aim is to push forward therapeutics and diagnostics innovation.